Studies show that rapid weight loss from any causeincluding GLP-1 therapyincreases gallstone development, particularly in patients with genetic predisposition
Neglia, J
Hence, we propose a novel immunometabolic pathway, where high glucose levels during hyperglycemia could lead to lower GSH levels, through consumption of GSH by hemoglobin- and membrane- AGE, thus disrupting the balance between GSSG formation and reduction
Rather, it reveals predispositions in peptide pathways that should be interpreted alongside clinical history, prior medication trials, and biomarker data
Conclusion While this study identifies a potential safety signal between semaglutide use and bile duct cancer, causality cannot be established
Subject to eligibility criteria